北陆药业2025年前三季度业绩稳健增长，净利润大幅提升81.10%！

Core Insights - Beilu Pharmaceutical (300016) reported strong performance in Q3 2025, with revenue reaching 873 million yuan, a year-on-year increase of 19.59%, and net profit attributable to shareholders at 44.18 million yuan, up 81.10% [1] - The growth in net profit was driven by the implementation of centralized procurement products and expansion in non-centralized procurement products and overseas markets [1] - The company plans to raise up to 300 million yuan through a simplified procedure for issuing shares to specific investors, aimed at funding various projects and supplementing working capital [2] Financial Performance - For the first three quarters of 2025, Beilu Pharmaceutical achieved operating revenue of 873 million yuan, a 19.59% increase year-on-year [1] - Net profit attributable to shareholders was 44.18 million yuan, reflecting an 81.10% increase compared to the previous year [1] - The net profit excluding non-recurring gains and losses was 33.68 million yuan, up 33.53% year-on-year [1] Strategic Developments - The company is focusing on a dual-driven strategy of "chemical drugs + traditional Chinese medicine" while enhancing its presence in both domestic and international markets [2] - Significant progress was made by the subsidiary Haichang Pharmaceutical, including the approval of several chemical raw materials and obtaining market access in Korea and India [2] - The funds raised will support the construction of new production lines and enhance the company's operational capabilities [2]